Abstract
Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 261-267 |
| Number of pages | 7 |
| Journal | Diabetes and Metabolism |
| Volume | 22 |
| Issue number | 4 |
| Publication status | Published - Jul 1996 |
| Externally published | Yes |
Fingerprint
Keywords
- growth hormone
- insulin resistance
- insulin sensitivity
- insulin-like growth factor-I
- Type 2 diabetes mellitus
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Froesch, E. R., Bianda, T., & Hussain, M. (1996). IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance. Diabetes and Metabolism, 22(4), 261-267.